AR and prostate carcinoma: SCD: SCD is upregulated in many cancers, including androgen receptor (AR)+ LNCaP prostate cancer cells [74], ErbB2-driven breast cancer cells [75], pancreatic cancer cells [76], glioblastoma cells [77], non-small-cell lung cancer patient samples (NSCLC) [78], and gastric cancer cells [79].